Background There are a number of instruments that describe severity and progression of
multiple sclerosis and they are increasingly used as endpoints to assess the effectiveness of …

Due to the heterogeneous nature of the disease, it is a challenge to capture disease activity
of multiple sclerosis (MS) in a reliable and valid way. Therefore, it can be difficult to assess …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Background The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a
phase 2 trial of previously untreated patients with relapsing-remitting multiple sclerosis. We …

Background The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in
previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess …

Abstract The Paced Auditory Serial Addition Test (PASAT)[Gronwall, D., & Sampson,
H.(1974). The psychological effects of concussion. Auckland, New Zealand: Auckland …

Most patients with multiple sclerosis (MS) eventually experience walking disability. The
objective of this review was to evaluate the clinical utility of measures specific for walking in …

Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor
function in people with multiple sclerosis. This phase III study assessed efficacy and safety of …

Despite that the availability of new therapeutic options has expanded the multiple sclerosis
(MS) disease-modifying therapy arsenal, interferon β (IFN-β) remains an important therapy …

Gray matter brain structures, including deep nuclei and the cerebral cortex, are affected
significantly and early in the course of multiple sclerosis and these changes may not be …